Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding: Mechanistic Insights and Research Implications

Study Background and Research Question

The renin-angiotensin system (RAS) is a foundational signaling cascade in cardiovascular biology, orchestrating blood pressure homeostasis and fluid balance through a series of peptide intermediates. Angiotensin II (1–8) and its enzymatically derived fragments, including Angiotensin 1/2 (2-7), are well characterized for their roles as vasoconstrictor peptides and in aldosterone release stimulation. The emergence of SARS-CoV-2, the causative agent of COVID-19, has brought renewed attention to RAS, particularly because the virus exploits angiotensin-converting enzyme 2 (ACE2) as a primary entry receptor. However, alternative viral entry pathways, such as the AXL receptor, have also been implicated, especially in tissues with low ACE2 expression. This raises critical questions about how endogenous RAS peptides may modulate viral-host interactions and influence infection dynamics.

Key Innovation from the Reference Study

Oliveira et al. (2025) provide a significant advance by demonstrating that naturally occurring angiotensin peptides—including not only canonical forms like angiotensin II, but also N- and C-terminal truncated fragments—directly enhance the binding of the SARS-CoV-2 spike protein to host cell receptors, especially AXL. Notably, the study reveals that certain angiotensin fragments are even more potent than their parent molecules in potentiating spike–AXL interactions, suggesting a nuanced regulatory landscape at the interface of RAS and viral pathogenesis. This mechanistic link between cardiovascular signaling peptides and viral entry receptor activation represents a new paradigm for understanding COVID-19 susceptibility and disease progression.

Methods and Experimental Design Insights

The investigators employed antibody-based binding assays to quantitatively assess the interaction between the SARS-CoV-2 spike protein and three key host cell receptors: ACE2, NRP1, and AXL. A panel of angiotensin peptides—including angiotensin I (1–10), angiotensin II (1–8), angiotensin (1–7), angiotensin (1–6), and various N-terminal and C-terminal truncated fragments (e.g., angiotensin III [2–8], angiotensin IV [3–8], angiotensin (2–7), angiotensin (5–7))—were systematically evaluated for their ability to modulate spike-receptor binding. The design allowed the team to dissect the impact of specific peptide truncations and sequence modifications (such as tyrosine substitution or phosphorylation) on the viral-host interface. These assays were performed under controlled conditions to isolate the effect of each peptide variant, providing robust comparative data.

Core Findings and Why They Matter

The study's central finding is that several angiotensin-derived peptides markedly increase the binding affinity of the SARS-CoV-2 spike protein for the AXL receptor, with some fragments achieving a two- to three-fold enhancement according to the reference study. Among these, C-terminally truncated peptides (such as angiotensin [1–7] and [1–6]) showed similar enhancement as angiotensin II, but N-terminal fragments (notably angiotensin IV [3–8], angiotensin III [2–8], and angiotensin [2–7]) displayed even greater potentiation, with angiotensin IV producing up to a 2.7-fold increase in spike–AXL binding. Importantly, the parental angiotensin I (1–10) did not affect spike–AXL interactions, underscoring the functional specificity conferred by peptide length and sequence.

Modifications at the tyrosine residue (position 4)—either by substitution with valine or by phosphorylation—further amplified spike–AXL binding, highlighting a possible structural motif mediating the effect. While the enhancement was most pronounced for spike–AXL binding, angiotensin IV also increased spike binding to ACE2 and NRP1, albeit to a lesser extent. These findings imply that RAS peptides, particularly non-canonical fragments, might act as endogenous modulators of viral entry and could help explain interindividual differences in COVID-19 susceptibility and severity—especially in the context of cardiovascular disease or hypertension, where RAS activity is dysregulated.

Comparison with Existing Internal Articles

Internal resources contextualize these mechanistic findings within broader research workflows. For example, the article "Angiotensin Peptides Boost SARS-CoV-2 Spike–Receptor Binding" corroborates the central claim of Oliveira et al. (2025), emphasizing the amplification of spike–AXL binding by endogenous RAS peptides and framing this as a new molecular intersection between cardiovascular and viral pathobiology.

Other internal analyses, such as "Angiotensin 1/2 (2-7): From Mechanistic Understanding to..." and "Angiotensin 1/2 (2-7): Expanding Horizons in Blood Pressure Regulation Research", review the unique roles of Angiotensin 1/2 (2-7) (the ARG-VAL-TYR-ILE-HIS-PRO peptide) in both classic blood pressure regulation research and emerging viral studies. These articles highlight how Angiotensin 1/2 (2-7)'s properties as a vasoconstrictor peptide and its role in aldosterone release stimulation can be leveraged in advanced research models, particularly as scientists seek to unravel how cardiovascular peptides influence viral infectivity and pathogenesis.

Limitations and Transferability

Several important limitations merit consideration. First, the reported enhancement of spike–AXL binding was observed in vitro using antibody-based binding assays and may not fully recapitulate the complexity of cellular or in vivo environments. Second, while the study establishes a clear mechanistic link between angiotensin peptide fragments and viral-receptor interaction, the downstream effects on viral entry, replication, and disease outcome were not directly assessed. The scope was restricted to binding events, and further work is necessary to determine whether these findings translate into altered infectivity or clinical manifestations.

Additionally, the concentration ranges and modifications of angiotensin fragments used in the assays may not mirror endogenous levels under physiological or pathological conditions. As such, caution is warranted in extrapolating these results to human disease or therapeutic interventions. The interplay between RAS modulation, blood pressure regulation, and viral susceptibility remains a complex and evolving topic, demanding integrative approaches across molecular, cellular, and clinical studies.

Why this cross-domain matters, maturity, and limitations

The intersection of cardiovascular peptide signaling and viral pathogenesis, as demonstrated by Oliveira et al. (2025), is of high translational interest. Understanding how angiotensin fragments like Angiotensin 1/2 (2-7) can modulate SARS-CoV-2 entry mechanisms may inform both infectious disease and hypertension research. However, the evidence remains at the mechanistic and preclinical level; clinical relevance and therapeutic implications have yet to be established. Researchers should recognize these findings as a foundation for hypothesis generation and as a rationale for integrative experimental models rather than as a basis for immediate clinical translation.

Protocol Parameters

• Peptide concentration for in vitro binding assays: Typical concentrations used in the reference study ranged from low nanomolar to micromolar; titrations are recommended to define dose-response relationships.
• Sequence specificity: Fragments such as Angiotensin 1/2 (2-7) (ARG-VAL-TYR-ILE-HIS-PRO) can be selected to probe the impact of N- and C-terminal truncations on spike–receptor interactions.
• Modification controls: Consider including variants with tyrosine substitution or phosphorylation to assess structure–activity relationships, as these modifications enhanced spike–AXL binding in the reference study.
• Receptor panel: Simultaneously assess binding to ACE2, AXL, and NRP1 to differentiate receptor-specific effects of each peptide fragment.
• Workflow recommendations: Use high-purity, well-characterized peptides, store aliquots at −20°C, and limit freeze–thaw cycles to maintain peptide integrity, as recommended in internal workflow guides.

Research Support Resources

For researchers seeking to reproduce or extend these findings, Angiotensin 1/2 (2-7) (SKU A1050) is available as a high-purity peptide tool. This reagent supports rigorous blood pressure regulation research and mechanistic studies on renin-angiotensin signaling pathway dynamics, as well as emerging models of viral pathogenesis. For detailed protocols and workflow enhancements, consult internal articles and ensure adherence to best storage and handling practices. APExBIO supplies Angiotensin 1/2 (2-7) strictly for scientific research use, not for diagnostic or therapeutic applications.